Improved overall survival in melanoma with combined dabrafenib and trametinib.

@article{Robert2015ImprovedOS,
  title={Improved overall survival in melanoma with combined dabrafenib and trametinib.},
  author={Caroline Robert and Bogusława Karaszewska and Jacob Schachter and Piotr Lukasz Rutkowski and Andrzej Adam Mackiewicz and Daniil Stroiakovski and Michael Lichinitser and Reinhard Dummer and F. Grange and Laurent Mortier and Vanna Chiarion-Sileni and Kamil Drucis and Ivana Krajsov{\'a} and Axel Hauschild and Paul C. Lorigan and Pascal Wolter and Georgina V. Long and Keith T. Flaherty and Paul Nathan and Antoni Ribas and Anne Marie Martin and Peng Sun and Wendy A. Crist and Jeffrey J. Legos and Stephen D. Rubin and Shonda M Little and Dirk Schadendorf},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 1},
  pages={
          30-9
        }
}
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients. METHODS In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a… 

Figures and Tables from this paper

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

  • G. LongJ. Weber K. Flaherty
  • Medicine, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
Dabrafenib plus trametinib results in a median OS of more than 2 years in BRAF inhibitor-naive patients with BRAF V600 mutation-positive metastatic melanoma, and approximately 20% were progression free at 3 years.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

First-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAFV600 Mutation

Dabrafenib plus trametinib provides an important treatment option for patients with BRAFV600 mutation-positive unresectable or metastatic melanoma, and does not increase overall toxicity relative to dabrafenIB or vemurafenib monotherapy.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvantUse of placebo and was not associated with new toxic effects.

Combined Therapy with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience

The data from BRAF-mutated metastatic melanoma patients treated with daily oral dabrafenib 300 mg and trametinib 2 mg are in line with the scientific literature in terms of both safety and effectiveness in a real-life setting.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

  • G. LongK. Flaherty J. Grob
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
It is demonstrated that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations

The mechanism of action of the combination of dabrafenib and trametinib, its evolution through Phase I, II and III clinical trials and its current use in the management of patients with advanced melanoma are summarized.

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma

XL888 in combination with vemurafenib has clinical activity in patients with advanced BRAFV600-mutant melanoma, with a tolerable side-effect profile.
...

References

SHOWING 1-10 OF 28 REFERENCES

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

A combination of dabraenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.

Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma

Dabrafenib and trametinib were approved for use as monotherapies in BRAF-mutant metastatic melanoma by the U.S. Food and Drug Administration (FDA) in 2013, and most recently, their use in combination

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

  • Kevin B. KimR. Kefford K. Lewis
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
The response rate for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma, and minimal clinical activity was observed as sequential therapy in patients previously treated with a BRAF inhibitor suggest that BRAf-inhibitor resistance mechanisms likely confer resistance to MEK- inhibitor monotherapy.

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

This Phase III study was conducted to confirm the superiority of D+T over D in pts with BRAFV600E/K mutant MM, and the primary endpoint was overall response rate (ORR), PFS and reduced frequency of cuSCC.

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.

Improved survival with ipilimumab in patients with metastatic melanoma.

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.